About Syntaxin
Syntaxin is a Healthcare company based in Abingdon (United Kingdom) founded in 2005, and was acquired by Ipsen in July 2013. Bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. Syntaxin has raised $62.01 million across 2 funding rounds from investors including Ipsen, Abingworth and Life Sciences Partners. Its focus areas include Diversified Pharmaceuticals and Drugs. Its competitors include Merck and Astrazeneca.
Company details
Syntaxin was founded in 2005 in Abingdon, United Kingdom, as a biopharmaceutical company focused on bacterial-based protein therapeutics. These therapeutics were engineered for treating neurological, inflammatory, and endocrine diseases through a proprietary platform involving domain substitution of bacterial proteins. Novel cell-specific biotherapeutics that inhibit cell secretion were produced as a result. The company was acquired by Ipsen in March 2013, with its name changed to Ipsen Bioinnovation in March 2015.
- Headquarters Abingdon, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website syntaxin.com
- Social LinkedIn
- Acquired by Ipsen (Jul 2013)
Funding Insights of Syntaxin
Syntaxin has successfully raised a total of $62.01M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $29 million completed in November 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $62.01M
- Total Rounds 2
- Last Round Series C — $29M
- First Round $33.01M
(Oct 2007)
- Investors Count 10
All 2 funding rounds of Syntaxin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2010 | $29M | Series C | – | – | |
| Oct 2007 | $33.01M | Series B | – | – |
10 investors in total: 10 institutional.
Investors in Syntaxin
Syntaxin has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Ipsen, Abingworth and Life Sciences Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US | seventure.fr | Paris, France | ||
Life science companies are funded through venture capital investments. | lundbeckfonden.com | Copenhagen, Denmark | ||
Growth-stage life sciences and tech companies in Europe are funded. | 1998 | questforgrowth.com | Leuven, Belgium | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | 1929 | ipsen.com | ||
| jnjinnovation.com | ||||
Innovative life sciences companies are supported through substantial investments. | lsp.nl |
Investor details for Syntaxin
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Syntaxin
738 people are tracked at Syntaxin (380 in leadership, 13 in board & advisors, 345 in team).
| Name | Role | Group |
|---|---|---|
Aurélien Biechy | Senior Director IP | Leadership |
Dr Fiona Maxwell | Vice President, Head Of Early Stage Clinical Development | Leadership |
Luis Zuniga Dnp | Regional Field Medical Director | Leadership |
Yu Fu | Medical Information Director | Leadership |
David Loew | CEO | Leadership |
Torianio White | Director Medical Affairs Training | Leadership |
Caroline Boin-Margerit | VP Corporate Communications | Leadership |
David Gruber | Senior Director Of Bioprocess Development (usp & Dsp) | Leadership |
Helene. Mathiex-Fortunet | Vice President Drugdevelopment- Primary Careproducts | Leadership |
Karen Martin | Svp, Chief IP Counsel | Leadership |
Stéphane Masseran | SVP & Chief Procurement Officer; Head Of Global Real Estate | Leadership |
Vincent Berny | Head Of Global Product Quality | Leadership |
Jennifer Glennon | Senior Vice President, Global Portfolio Operations | Leadership |
Yacoub Adjibade | Vice President | Leadership |
Chris Watters | Ad Interim Senior Vice President, Franchise Head, Oncology Business Unit | Leadership |
Sarah O'Mahony | Global Head Of Asset Operations Neuroscience | Leadership |
Sarah Desi Arragon | Senior Director, Strategic Alliance Management | Leadership |
Josep Catllà | EVP & Chief Corporate Affairs Officer | Leadership |
Anne-Sophie Dubromer | Global Digital Transformation And Communication Director | Leadership |
Jean-Francois Muller | Vice President Procurement Americas | Leadership |
718 more people are available in the full profile.
Complete people profiles for Syntaxin
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Syntaxin
4 dated milestones of Syntaxin across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Syntaxin is founded.
- Funding First funding round of $33.0M.
- Funding Latest funding round, Series C, of $29.0M.
- Exit Acquired by Ipsen.
Competitors of Syntaxin
Syntaxin has 2 listed competitors in our database. They include Merck and Astrazeneca.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | 781 | Pharmaceutical products are manufactured and marketed worldwide. | ||
| astrazeneca.com | 1913 | Cambridge, United Kingdom | 83,100 | Pharmaceutical and biologics products are developed and distributed worldwide. |
Detailed competitors of Syntaxin
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Syntaxin
Syntaxin was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Syntaxin is headquartered in Abingdon, United Kingdom. It is registered at Abingdon, Oxfordshire, United Kingdom.
Syntaxin is a funded company, having raised a total of $62.01M across 2 funding rounds to date. The company's 1st funding round was a Series B of $33.01M, raised on Oct 2007.
Syntaxin was founded in 2005 in Abingdon, United Kingdom, as a biopharmaceutical company focused on bacterial-based protein therapeutics. These therapeutics were engineered for treating neurological, inflammatory, and endocrine diseases through a proprietary platform involving domain substitution of bacterial proteins. Novel cell-specific biotherapeutics that inhibit cell secretion were produced as a result. The company was acquired by Ipsen in March 2013, with its name changed to Ipsen Bioinnovation in March 2015.
Syntaxin's top competitors include Merck and Astrazeneca.
Syntaxin has 10 investors. Key investors include Ipsen, Abingworth, Life Sciences Partners, Quest for Growth, and SR One.
Yes. Syntaxin was acquired by Ipsen in July 2013.